Scalable Downstream Strategies for Purification of Recombinant Adeno-Associated Virus Vectors in Light of the Properties

被引:50
|
作者
Qu, Weihong [1 ,2 ,3 ,4 ]
Wang, Mingxi [1 ,2 ,3 ]
Wu, Yaqing [1 ,2 ,3 ]
Xu, Ruian [1 ,2 ,3 ]
机构
[1] Huaqiao Univ, Sch Med, Yunleung Lab Mol Diagnost, Quanzhou 362021, Peoples R China
[2] Huaqiao Univ, Inst Mol Med, Quanzhou 362021, Peoples R China
[3] Minist Educ, Engn Res Ctr Mol Med, Xiamen 361021, Peoples R China
[4] Jiujiang Univ, Coll Med & Life Sci, Jiujiang 332000, Jiangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Clinical application; downstream purification; large scale; physicochemical properties; purification strategy; rAAV vector; ION-EXCHANGE CHROMATOGRAPHY; LIPOPROTEIN-LIPASE DEFICIENCY; SERUM-FREE PRODUCTION; HUMAN GENE-THERAPY; VIRAL VECTORS; HIGH-TITER; COLUMN CHROMATOGRAPHY; EMPTY CAPSIDS; LARGE-SCALE; IN-VIVO;
D O I
10.2174/1389201016666150505122228
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recombinant adeno-associated virus (rAAV) vector is one of the promising delivery tools for gene therapy. Currently, hundreds of clinical trials are performed but the major barrier for clinical application is the absence of any ideal large scale production technique to obtain sufficient and highly pure rAAV vector. The large scale production technique includes upstream and downstream processing. The upstream processing is a vector package step and the downstream processing is a vector purification step. For large scale downstream processing, the scientists need to recover rAAV from dozens of liters of cell lysate or medium, and a variety of purification strategies have been developed but not comprehensively compared till now. Consequently, this review will evaluate the scalable downstream purification strategies systematically, especially those based on the physicochemical properties of AAV virus, and attempt to find better scalable downstream strategies for rAAV vectors.
引用
收藏
页码:684 / 695
页数:12
相关论文
共 50 条
  • [1] Scalable Downstream Purification of Recombinant Adeno-associated Viral Vectors
    Schofield, M.
    Marchand, N.
    Kavara, A.
    Hejmowski, A.
    Tansey, S.
    Channawar, R.
    Olson, M.
    MacIntyre, A.
    Huato, J.
    Boenning, K.
    Collins, M.
    Cameau, E.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A106 - A106
  • [2] A simplified purification protocol for recombinant adeno-associated virus vectors
    Potter, Mark
    Lins, Bridget
    Mietzsch, Mario
    Heilbronn, Regine
    Van Vliet, Kim
    Chipman, Paul
    Agbandje-McKenna, Mavis
    Cleaver, Brian D.
    Clement, Nathalie
    Byrne, Barry J.
    Zolotukhin, Sergei
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2014, 1 : 14034
  • [3] Purification of Recombinant Adeno-Associated Viral Vectors
    Pan, Xing
    MOLECULAR THERAPY, 2020, 28 (04) : 538 - 538
  • [4] Biosafety of Recombinant Adeno-associated Virus Vectors
    Dismuke, David J.
    Tenenbaum, Liliane
    Samulski, R. Jude
    CURRENT GENE THERAPY, 2013, 13 (06) : 434 - 452
  • [5] Production of recombinant adeno-associated virus vectors
    Zolotukhin, S
    HUMAN GENE THERAPY, 2005, 16 (05) : 551 - 557
  • [6] Targeting of recombinant adeno-associated virus vectors
    Hallek, M
    Büning, H
    Ried, M
    Perab, L
    Kofler, D
    Gerner, F
    Wendtner, CM
    Leike, K
    Huttner, N
    Hutter, M
    CANCER GENE THERAPY, 2001, 8 (09) : 688 - 688
  • [7] A novel method for purification of recombinant adeno-associated virus vectors on a large scale
    WU Xiaobing
    Laboratory of Morphology
    ChineseScienceBulletin, 2001, (06) : 485 - 489
  • [8] Production and purification of recombinant adeno-associated virus
    Hauswirth, WW
    Lewin, AS
    Zolotukhin, S
    Muzyczka, N
    VERTEBRATE PHOTOTRANSDUCTION AND THE VISUAL CYCLE, PT B, 2000, 316 : 743 - 761
  • [9] Progress Towards a Scalable Manufacturing Platform for Recombinant Ancestral Adeno-Associated Virus Vectors
    Gu, Bingnan
    Seth, Anandita
    Vitelli, Francesca
    MOLECULAR THERAPY, 2017, 25 (05) : 227 - 227
  • [10] Recombinant adeno-associated virus vectors for gene therapy
    Conlon, TJ
    Flotte, TR
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (07) : 1093 - 1101